utreloxastat   Click here for help

GtoPdb Ligand ID: 13260

Synonyms: compound C9 [WO2020081879A2] | PTC-857 | PTC857
Compound class: Synthetic organic
Comment: Utreloxastat (PTC-857) is described as a 15-lipoxygenase inhibitor in its INN record. It was developed for potential to treat α-synucleinopathies, tauopathies, ALS and other brain injuries/insults [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 8
Topological polar surface area 34.14
Molecular weight 276.41
XLogP 4.94
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCCCCCCCC1=C(C)C(=O)C(=C(C)C1=O)C
Isomeric SMILES CCCCCCCCCC1=C(C(=O)C(=C(C1=O)C)C)C
InChI InChI=1S/C18H28O2/c1-5-6-7-8-9-10-11-12-16-15(4)17(19)13(2)14(3)18(16)20/h5-12H2,1-4H3
InChI Key IJWAQTHZBDBIID-UHFFFAOYSA-N
References
1. Hinman AW, Holst CR, Minella A, Mollard P, Pintchovski S, Trimmer JK, Torrey E. (2020)
2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS.
Patent number: WO2020081879A2. Assignee: Ptc Therapeutics, Inc.. Priority date: 17/10/2019. Publication date: 23/04/2020.